Dare Bioscience

Dare Bioscience R&D per Employee

The R&D Spending per Employee of Dare Bioscience (DARE) as of Oct 30, 2026 is 263.02 M USD. In the previous year, R&D Spending per Employee was 676,438.48 USD — a change of 38,782.58% (higher).

R&D per Employee

263.02 MUSD

YoY

38,782.58%

Last updated:

R&D Spending per Employee of Dare Bioscience is 2025 263.02 M USD. R&D Spending per Employee of Dare Bioscience was 2024 676,438.48 USD. It decreases by 38,782.58% higher compared to the previous year.

The Dare Bioscience R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
305,428.57 USD
Jan 1, 2019
406,957.52 USD
Jan 1, 2020
989,019.86 USD
Jan 1, 2021
1.46 M USD
Jan 1, 2022
1.43 M USD
Jan 1, 2023
1.03 M USD
Jan 1, 2024
676,438.48 USD
Jan 1, 2025
263.02 M USD
The Dare Bioscience R&D per Employee history
YEARR&D per EmployeeYoY
263.02 MUSD+38,782.58%
676,438.48USD-34.05%
1.03 MUSD-28.31%
1.43 MUSD-1.88%
1.46 MUSD+47.42%
989,019.86USD+143.03%
406,957.52USD+33.24%
305,428.57USD+551.33%
46,892.81USD-96.43%
1.31 MUSD+6.23%
1.24 MUSD+120.42%
560,571.43USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience Stock analysis

What does Dare Bioscience do? Daré Bioscience, Inc. develops and commercializes pharmaceutical products in women's reproductive health, focusing on non-hormonal contraceptive solutions. Its lead product, Ovaprene, is a clinical stage intravaginal ring designed to provide multi-week protection without intervention during intercourse. The ring features a permeable mesh barrier and localized spermiostatic agent delivery, combining barrier and spermicidal mechanisms to achieve efficacy comparable to diaphragms and short-acting hormonal methods like oral pills and vaginal rings. The company targets women seeking non-hormonal contraceptive options, with Ovaprene positioned as an alternative to existing hormonal products and barrier methods. The firm generates revenue through the development and commercialization of Ovaprene, aiming to address unmet needs in women's reproductive health. Ovaprene is designed to offer a non-hormonal, user-friendly alternative to traditional hormonal contraceptives, appealing to consumers who prefer avoiding hormonal side effects. The company's focus on clinical development and product commercialization aligns with the market demand for innovative, non-hormonal contraceptive options in women's health. Dare Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dare Bioscience stock

R&D Spending per Employee of Dare Bioscience is 263.02 M USD in 2025.

R&D Spending per Employee of Dare Bioscience changed from 676,438.48 USD to 263.02 M USD, representing a 38,782.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Dare Bioscience since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Dare Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Dare Bioscience

All Key Metrics — Dare Bioscience